Program
Anti-FLT3/CD3 Bispecific Antibody CLN-049
Its studies are mostly in Leukemia, Myeloid, Acute, led by Cullinan Therapeutics.
Furthest: phase 2, since Oct 26, 20212 company-led studies, 2 open or runningNext primary completion: Sep 30, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Cullinan Therapeutics | 22 open or running | phase 2since Oct 26, 2021 | Oct 26, 2021 | Sep 30, 2027phase 1 · NCT07722767 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 26, 2021First study: phase 2 study in Leukemia, Myeloid, AcuteFirst studyNCT05143996 · 275 planned · United States
- Jul 15, 2026Phase 1 study in Leukemia, Myeloid, AcuteNCT07722767 · 90 planned · United States
Ahead
- Sep 30, 2027Primary completion: phase 1 study in Leukemia, Myeloid, AcuteNCT07722767
- Dec 30, 2029Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT05143996
TargetBeta
“A T-cell-engaging, humanized, Fc-silenced immunoglobulin G1 (IgG1)-based bispecific antibody directed against both the tumor-associated antigen (TAA) FLT3 tyrosine kinase receptor (Fms-like tyrosine kinase 3; FLT3; FLT-3; CD135; fetal liver kinase-2; FLK2) and the CD3 antigen found on T-lymphocytes,”NCIt, by rule
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07722767Leukemia, Myeloid, Acute · United States | 1 | Not yet recruiting | Sep 30, 2027 | 90 |
| NCT05143996Leukemia, Myeloid, Acute · United States | 2 | Recruiting | Dec 30, 2029 | 275 |
How it is read
Names in the registry
- “CLN-049”, 2 entries
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.